MedPath

Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis

Phase 3
Completed
Conditions
Head and Neck Cancer
Interventions
Registration Number
NCT02303197
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Brief Summary

This study evaluates the efficiency and safety of ChiNing decoction to head and neck cancer patients with radioactive stomatitis. Half of participants will receive ChiNing decoction, while others will receive recombinant human epidermal growth factor (rhEGF) spray.

Detailed Description

This study uses randomized, controlled clinical research methods, through the observation of the treatment group (ChiNing decoction orally) and control group (recombinant human epidermal growth factor rhEGF spray on oral mucosal surface ) at different time points before and after radiotherapy, to evaluate the radiotherapy of acute radiation oral mucosa reaction (RTOG grade), quality of life score (EORTCQLQ-H\&N35 scale), oral pain (VAS score) and patient body weight changes of the two groups. At the same time,this study takes cast-off cells of oral mucosal to observe the microscopic characteristics of oral mucosa, and uses the ELISA method to detect IL-6 and TNF- alpha content in the saliva before and after radiotherapy.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Head and neck cancer patients with pathology and / or cytologic diagnosis;
  • Age 18~75 years old;
  • The expected life is more than 3 months;
  • The Karnofsky score (Karnofsky) ≥70 points;
  • The first course of radiotherapy in patients;
  • Patients had not received any anti tumour therapies for example of operation, radiotherapy,chemotherapy, biological treatment or isotope therapy system;
  • Patients volunteered to participate in this test and signed the informed consent, understand the purpose and test steps of the test, good compliance, comply with the relevant requirements of this test scheme;
  • No history of oral ulcer and salivary gland diseases
Exclusion Criteria
  • That do not meet the above the inclusion criteria;
  • Advanced critical cases, the expected survival is less than 3 months;
  • The patients had serious complications, such as cachexia, hepatic encephalopathy, gastrointestinal bleeding and coagulation functionobstruction, su ch as abnormal;
  • The submandibular gland pathological changes;
  • During radiotherapy taking other drugs in patients with treatment of stomatitis;
  • The patients with serious heart, brain, liver, kidney function

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ChiNing decoctionChiNing decoction60ml ChiNing decoction by mouth,three times a day for 46 days.
Primary Outcome Measures
NameTimeMethod
Grading standard of RTOG in acute radiation injury of oral mucosal8 days

Score before the radiotherapy and every 1 week after the begining of the radiotherapy and after the end of radiotherapy

Secondary Outcome Measures
NameTimeMethod
The visual analogue scale of oral pain8 days

Score before the radiotherapy and every 1 week after the begining of the radiotherapy and after the end of radiotherapy

EORTCQLQ-H&N358 days

Score before the radiotherapy and every 1 week after the begining of the radiotherapy and after the end of radiotherapy

patient body weight changes8 days

Score before the radiotherapy and every 1 week after the begining of the radiotherapy and after the end of radiotherapy

Safety index2 days

Chech the blood routine, urine routine, liver and kidney function, electrocardiogram before and after the radiotherapy

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute and Hospital

🇨🇳

Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath